HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE Italy Mid Cap: DIA) today announced the introduction of an automated, ...
QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing. On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test ...
QIAGEN leverages QuantiFERON®-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also showcased at the ...
Jan. 11, 2005 — The U.S. Food and Drug Administration (FDA) has approved a test to identify individual patient variations in drug metabolism; an implant system that simplifies the arthroscopic ...
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Health Canada regulatory approval of QuantiFERON®-TB Gold Plus ...
Clinical Infectious Diseases publishes clinically relevant articles on the pathogenesis, clinical investigation, medical microbiology, diagnosis, immune mechanisms, and treatment of diseases caused by ...
Tuberculosis, also known as TB, is an illness that affects the lungs and is caused by a type of bacteria called Mycobacterium tuberculosis complex. TB can spread when a person with the illness coughs, ...
The US Food and Drug Administration (FDA) has approved QuantiFERON-TB Gold Plus (QFT-Plus); (QUIAGEN NV), a fourth generation latent tuberculosis (TB) blood test that combines CD4/CD8 ratio design to ...
Qiagen ($QGEN) pointed to a head-to-head comparison study in The Lancet showing that its Quantiferon-TB Gold tuberculosis test could be more accurate at detecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results